Innovative research and development for new drugs for intractable diseases centered on cancer
As one of the innovative drug discovery, we are developing anti-CD4 antibody as a therapeutic drug for solid tumors. Discussions are underway to confirm safety in clinical trials and find partner companies to continue research and development.
- Establishment Date
- April 2012
- Drug development
- CEO and COO Satoshi Ito
Point of KII view
With the new idea of removing CD4 positive cells, we hope that it will be launched as a new cancer immunotherapeutic drug.
KII growth support
Financing lead, recruitment support for management department managers, candidate selection and negotiation support for business partners